BLEND
CJC-1295 + Ipamorelin
CJC-1295 (No DAC) + Ipamorelin Blend
10mg $79This research blend combines CJC-1295 (without Drug Affinity Complex) and Ipamorelin, representing a dual-mechanism approach to growth hormone axis research. CJC-1295 is a modified GHRH analog while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist.
Dual-Mechanism Approach
Combines GHRH receptor agonism (CJC-1295) with GHSR agonism (Ipamorelin) for synergistic GH axis research.
Selective GH Secretagogue
Ipamorelin demonstrates high selectivity for GHSR without significant effects on cortisol or prolactin in preclinical studies.
Modified GHRH Analog
CJC-1295 (No DAC) features four amino acid substitutions enhancing stability while maintaining GHRH receptor activity.
Ipamorelin: The first selective growth hormone secretagogue
Characterization of ipamorelin as a novel, selective GH secretagogue with minimal effects on ACTH, cortisol, and prolactin release.
| Product Name | CJC-1295 (No DAC) + Ipamorelin |
| CAS Numbers | 863288-34-0 (CJC) / 170851-70-4 (Ipamorelin) |
| Blend Ratio | 5mg CJC-1295 + 5mg Ipamorelin |
| Purity | ≥99% each component (HPLC) |
| Physical Form | White Lyophilized Powder |
| Storage | -20°C, protected from light |
| Certification | Third-party HPLC & MS verified |
| Intended Use | Research and laboratory use only |
